Tom 16, Nr 3 (2021)
Sprawozdanie z konferencji / Sprawozdanie
Opublikowany online: 2021-06-30
Wyświetlenia strony
162
Wyświetlenia/pobrania artykułu
440
Postępy farmakoterapii chorób układu sercowo-naczyniowego. Doniesienia z American Heart Association Scientific Sessions 2020
1
, 1
, 1
Folia Cardiologica 2021;16(3):214-218.
Streszczenie
Brak
Słowa kluczowe: AHA 2020Sesje Naukowe 2020American Heart Association
Referencje
- Guimarães HP, Lopes RD, de Barros E Silva PGM, et al. RIVER Trial Investigators. Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve. N Engl J Med. 2020; 383(22): 2117–2126.
- Teerlink JR, Diaz R, Felker GM, et al. GALACTIC-HF Investigators. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. N Engl J Med. 2021; 384(2): 105–116.
- Enjuanes C, Klip IT, Bruguera J, et al. Iron deficiency and health-related quality of life in chronic heart failure: results from a multicenter European study. Int J Cardiol. 2014; 174(2): 268–275.
- Anker SD, Kirwan BA, van Veldhuisen DJ, et al. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. Eur J Heart Fail. 2018; 20(1): 125–133.
- Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. CONFIRM-HF Investigators. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†. Eur Heart J. 2015; 36(11): 657–668.
- Ponikowski P, Kirwan BA, Anker SD, et al. AFFIRM-AHF investigators. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet. 2020; 396(10266): 1895–1904.
- Andrade JG, Wells G, Deyell M, et al. Cryoablation or drug therapy for initial treatment of atrial fibrillation. N Engl J Med. 2021; 384(4): 305–315.
- Wood FA, Howard JP, Finegold JA, et al. N-of-1 trial of a statin, placebo, or no treatment to assess side effects. N Engl J Med. 2020; 383(22): 2182–2184.
- Kalstad A, Myhre P, Laake K, et al. Effects of n-3 fatty acid supplements in elderly patients after myocardial infarction. Circulation. 2021; 143(6): 528–539.
- Reynolds HR, Maehara A, Kwong RY, et al. Coronary optical coherence tomography and cardiac magnetic resonance imaging to determine underlying causes of myocardial infarction with nonobstructive coronary arteries in women. Circulation. 2021; 143(7): 624–640.
